Corbus Pharmaceuticals Holdings Inc.
| NASDAQ: CRBP | Healthcare / Biotechnology / USA |
| 6.16 | -0.1100 | -1.75% | Vol 8.45K | 1Y Perf 3 632.14% |
| Oct 4th, 2023 16:00 DELAYED |
| BID | 5.75 | ASK | 6.87 | ||
| Open | 6.11 | Previous Close | 6.27 | ||
| Pre-Market | - | After-Market | 6.15 | ||
| - - | -0.01 -0.16% |
| Target Price | 3.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | -51.30 | Finscreener Ranking | ★★+ 48.07 | |
| Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ★★ 47.29 | |
| Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | ☆ 25.79 | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 36.62 | Earnings Rating | Strong Buy | |
| Market Cap | 27.25M | Earnings Date | 14th Nov 2023 | |
| Alpha | -0.03 | Standard Deviation | 0.31 | |
| Beta | 2.27 |
Today's Price Range 6.116.79 | 52W Range 2.1113.17 | 5 Year PE Ratio Range -10.80-2.80 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -1.26% | ||
| 1 Month | -5.71% | ||
| 3 Months | -20.23% | ||
| 6 Months | -9.65% | ||
| 1 Year | 3 632.14% | ||
| 3 Years | 248.33% | ||
| 5 Years | -12.31% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -130.58 | |||
ROE last 12 Months | -77.48 | |||
ROA (5Y Avg) | -37.86 | |||
ROA last 12 Months | -47.66 | |||
ROC (5Y Avg) | -164.19 | |||
ROC last 12 Months | -48.81 | |||
Return on invested Capital Q | -12.31 | |||
Return on invested Capital Y | -10.30 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.40 | ||||
| 0.43 | ||||
| 205.94 | ||||
| - | ||||
| -0.60 | ||||
| -0.32 | ||||
| 0.43 | ||||
| 0.33 | ||||
| -22 543 000.00 | ||||
| Forward PE | -0.65 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.80 | ||||
| 3.90 | ||||
| 0.26 | ||||
| 0.61 | ||||
| -167.80 | ||||
| Leverage Ratio | 1.70 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -40 823.80 | ||||
| -39 249.00 | ||||
| -1 666.60 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| -62.37 | ||||
| -18.13 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -3.10 | -2.05 | 33.87 |
| Q01 2023 | -4.09 | -4.24 | -3.67 |
| Q04 2022 | -2.10 | -2.61 | -24.29 |
| Q03 2022 | -1.80 | -2.10 | -16.67 |
| Q02 2022 | -1.80 | -2.10 | -16.67 |
| Q01 2022 | -2.70 | -2.40 | 11.11 |
| Q04 2021 | -3.30 | -2.40 | 27.27 |
| Q03 2021 | -3.60 | -0.60 | 83.33 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -2.06 | 33.55 | Positive |
| 12/2023 QR | -3.20 | -45.45 | Negative |
| 12/2023 FY | -11.52 | 4.79 | Positive |
| 12/2024 FY | -10.29 | -53.58 | Negative |
| Next Report Date | 14th Nov 2023 |
| Estimated EPS Next Report | -2.06 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 8.45K |
| Shares Outstanding | 4.42K |
| Shares Float | 4.12M |
| Trades Count | 266 |
| Dollar Volume | 53.40K |
| Avg. Volume | 8.82K |
| Avg. Weekly Volume | 6.68K |
| Avg. Monthly Volume | 8.59K |
| Avg. Quarterly Volume | 11.19K |
Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) stock closed at 6.27 per share at the end of the most recent trading day (a -2.64% change compared to the prior day closing price) with a volume of 4.37K shares and market capitalization of 27.25M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 141 people. Corbus Pharmaceuticals Holdings Inc. CEO is Yuval Cohen.
The one-year performance of Corbus Pharmaceuticals Holdings Inc. stock is 3632.14%, while year-to-date (YTD) performance is 5574.21%. CRBP stock has a five-year performance of -12.31%. Its 52-week range is between 2.11 and 13.1699, which gives CRBP stock a 52-week price range ratio of 36.62%
Corbus Pharmaceuticals Holdings Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 0.43, a price-to-sale (PS) ratio of 205.94, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -47.66%, a ROC of -48.81% and a ROE of -77.48%. The company’s profit margin is -%, its EBITDA margin is -39 249.00%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Corbus Pharmaceuticals Holdings Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-2.06 for the next earnings report. Corbus Pharmaceuticals Holdings Inc.’s next earnings report date is 14th Nov 2023.
The consensus rating of Wall Street analysts for Corbus Pharmaceuticals Holdings Inc. is Strong Buy (1), with a target price of $3, which is -51.30% compared to the current price. The earnings rating for Corbus Pharmaceuticals Holdings Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Corbus Pharmaceuticals Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Corbus Pharmaceuticals Holdings Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 29.27, ATR14 : 0.47, CCI20 : -153.96, Chaikin Money Flow : -0.09, MACD : -0.12, Money Flow Index : 45.41, ROC : -10.68, RSI : 43.14, STOCH (14,3) : 19.13, STOCH RSI : 0.42, UO : 44.98, Williams %R : -80.87), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Corbus Pharmaceuticals Holdings Inc. in the last 12-months were:
Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
CEO: Yuval Cohen
Telephone: +1 617 963-0100
Address: 500 River Ridge Drive, Norwood 02062, MA, US
Number of employees: 141
